Gilead Sciences stock heads into the open after a 0.24% gain
Published on 09/11/2026 at 07:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock closed at USD 145.16 on Nasdaq on September 10, 2026, up 0.24% from the prior session in currency in USD terms per Nasdaq data at Yahoo Finance. The move came as the shares tested an intraday range of roughly USD 143 to USD 146, leaving the stock near the upper end of its recent 52-week band. Today, investors are watching a new bullish analyst stance and the company’s presence at a major healthcare conference as potential catalysts ahead of the open.
September 10, 2026 in numbers
Gilead Sciences, Inc. (ISIN US3755581036, Nasdaq: GILD) ended trading on Nasdaq at USD 145.16 on September 10, 2026, after a 0.24% gain that reflected modest buying interest late in the session per the closing overview on Yahoo Finance. The stock’s intraday pattern showed a day low near USD 143 and a day high close to USD 146, keeping the close within a narrow range and still only modestly below the 52-week high level cited around USD 146 in recent market commentary. Per the same data set, the volume for the session stood in the typical millions of shares, broadly in line with the stock’s average turnover, and the price action slightly outperformed the tech-heavy Nasdaq Composite, which slipped around 0.6% on September 10, 2026 according to Zacks.
A key backdrop for the session was renewed analyst support. As MarketBeat reported on September 10, 2026, HSBC raised its price objective on Gilead Sciences from USD 155 to USD 175 and reiterated a buy rating, underscoring confidence in the company’s earnings and pipeline outlook. The stock also traded in the context of recent Q2 2026 results that topped consensus EPS by USD 0.50, as highlighted in a session wrap noting that Gilead Sciences stock closed at USD 145.65 on September 9, 2026 following the earnings beat according to Ad-hoc-news. That prior strength helped keep the shares near recent highs despite the broader index decline.
Today’s catalysts on September 11, 2026
Looking ahead to today’s session on September 11, 2026, Gilead Sciences is due to remain in focus thanks to ongoing analyst attention and investor outreach. The HSBC price target increase to USD 175 and maintained buy rating, reported on September 10, 2026 by Benzinga, provides a fresh reference point for market participants as they assess the stock’s valuation relative to its recent close. In addition, Gilead’s participation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a presentation held on September 10, 2026 according to GuruFocus, keeps the company in the discussion among healthcare investors, even though no new earnings figures were released at the event. Broader market conditions, including the recent decline in the Nasdaq Composite noted by Zacks, may also influence trading in Gilead Sciences today, given its listing on Nasdaq and sensitivity to sector sentiment.
